Abstract To mvestlgate the role of the renm-anglotensm system m the regulation of adrenal growth m deoxycortlcosterone (DOC)-salt hypertensive rats, and the adrenal gene exprewon of angiotensm ATI and AT2 receptors, three groups of unmephrectomlzed rats+DOC pellet+0 9% NaCl were given water (DOC), losartan (DOC-L), or ramlpril (DOC-R) by gavage Controls had sham surgery and water gavage Tall-cuff systohc and mean mtra-arterial blood pressures were slgmficantly higher m the three DOC groups than in controls and not different among the groups Adrenal weight of DOC was slightly but not significantly greater than that of controls, while those of DOC-L and DOC-R were greater than that of controls (P< 01). Northern blots showed that AT, and AT2 gene expresslon was slgmficantly reduced m DOC (by 33% and 60%), while that of AT, (but not AT?) was slgmfscantly reduced further (versus control and DOC) m DOC-L and DOC-R There were negative correlations between adrenal weight and AT, (r=-80, P< 0001) or ATI (r=-60, P< 005) We conclude that DOC-salt hypertension downregulates adrenal AT, and AT2 gene expression by different mechamsms. Removal of the effects of anglotensm by losartan or ramlprlldownregulates AT, further and promotes adrenal growth, indicating the presence of an AT,-mediated growth-mhlbltory actlon of anglotensm II on the adrenal gland These observations constitute an adchtlonal example of a growth-mhlbltory role for the AT, receptor, opposite to Its more common growth-promotmg actions m other organs and tissues. (Hypertension. 1997;29[part 2]:408-413.) Key Words l receptors, angiotensm II l gene expressron regulation l blotting, Northern l losartan l ramlprll l deoxycortlcosterone l rats T he circulating remn-anglotensm system has long been known to regulate vasoconstriction and aldosterone secretion, thus participating m blood pressure control and fluid homeostasis. Over the last few years, it has become apparent that local tissue renin-anglotensm systems play a major role m the regulation of growth processes. These effects have been described m tissues that are involved either m the pathogenesls or m the target organ damage of hypertension, eg, vascular smooth muscle,' cardlomyocytes,z mesangmm,3 endothehum," and neointima of injured vessels.5
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The actions of anglotensm II are exerted via activation of cell surface receptors. The development of specific nonpeptide antagonists for anglotensin II and their use m pharmacological and radlollgand binding expenments have permitted characterization of distinct receptor subtypes for this pressor peptlde. More recently, molecular probes for the study of receptor gene expresslon6J and expenments with gene transfections have been used to study the role of these receptor subtypes in medlatmg the actions of anglotensin II. The hemodynamlc and aldosterone secretion effects of anglotensm II are medrated by the AT1 receptor."JO Regarding the effects on cell growth, the prevailing view 1s that the AT, receptor mediates the growth-promotmg, while the AT, receptor mediates the opposing, antiproliferative actions of anglotensin II 11~ However, not all available evidence supports this view For example, AT, blockade by losartan does not prevent aortic hypertrophy and fibrosis during anglotensm II-mduced hypertension m the rat. 12 In contrast, AT2 blockade by specific antagonists inhibits aortlc hypertrophy and fibrosis m this model Also, AT1 blockade prevents neomtlmal growth after carotid artery injury m the rat. 13 These observations indicate the presence of growth-promoting actions for the AT2 receptor The adrenal gland expresses the genes encoding both AT, and AT2 receptors throughout fetal and adult life, 14~5 with the former predominating m the cortex and the latter m the medulla. In bovine adrenocortlcal cells in culture, anglotensm II has potent rmtogemc effects'6JT and mduces expression of proto-oncogenes, '8 both effects via the ATI receptor. In vlvo, It has been reported that the adrenal glands of rats with expenmental DOC-salt hypertension sustain weight reduction,*9 a change that 1s prevented by admmlstratlon of anglotensm I.20 The role of anglotensm II receptor subtypes m these effects of the renm-anglotensm system on adrenal growth has not been explored m this model
The alms of this study were threefold.
(1) to examme the role of the remn-anglotensm system m the regulation of the changes m growth of the adrenal gland induced by DOC-salt hypertension, (2) to define the specific pathways (AT, versus AT2 receptor-mediated) responsible for these growth processes, and (3) to assess the effects of DOC-salt hypertension, with or without blockade of the renin-angiotensm system, on the gene expression of AT, and AT2 receptors m the adrenal gland We used the converting enzyme mlubitor ramlpril and the AT, receptor blocker losartan for pharmacological blockade of the Selected Abbreviations  and Acronyms AT,, ATI = angrotensm receptor subtype 1, 2 )I GRE = glucocorticoid responsive element renm-angiotensm system and measured expression of angiotensin II receptor subtypes, AT, and ATP, m the adrenal glands of DOC-salt rats. Plasma rerun IS low m DOC-salt rats 3 weeks after mduction of hypertension21 and pharmacologmal blockade of the renm-angiotensm system does not modify blood pressure 21~2 Under these conditrons, the effects of ramipril and losartan on organ growth can be predominantly attributed to changes m local tissue angiotensm II, and more importantly, they are devoid of the confoundmg influence of changes m blood pressure by these agents
Methods

Treatment Groups
Five-week-old male Sprague Dawley rats (Harlan Inc), welghmg between 140 and 170 g, were randomly divided mto four groups (n=7 each) Animals were anesthetized with a single mtraperltoneal qectron of 80 mg/kg ketamme and 0 2 mg/kg xylazme Three groups were subjected to left nephrectomy and rmplantation of a DOC pellet (150 mg, Innovative Research) in the back of the neck, while the control group had sham nephrectomy After recovery from surgery, the rats m the three DOC groups were given 0 9% NaCl and 0 2% KC1 to drink ad hbitum, whrle the controls were given tap water In addmon, animals were given water (0 5 to I mL) via oral gavage, once a day for 3 weeks, containing either losartan (10 mg/kg per day, DOC-L group), ramrprrl (10 mgikg per day, DOC-R group), or no added drugs m the DOC-treated (DOC group) and m control (C group) ammals At the end of the 21-day treatment period, all rats were anesthetized as above, and the left carotid artery was catheterized for the measurement of MAP with a Statham 231D pressure transducer coupled to a Gould 2400s recorder (Gould Inc) MAP responses to bolus mJectlons of angrotensm I (50 rig/kg) and angrotensm II (50 rig/kg) were assessed in all four groups of rats to evaluate the effectiveness of the treatment with ramipril and losartan 13 All animal procedures were m accordance wrth the National Institutes of Health Guzdelmes for the Cure and Use of Laboratory Anwnals Body Weight and Systolic Blood Pressure Body weight was recorded at the begmnmg and at the end of the experiment Indirect tall-cuff systolic blood pressures were routmely measured m conscrous rats every 3 to 4 days for 21 days begmnmg 1 day before surgery A Narco Bra-Systems Electro-Sphygmomanometer was used for these measurements The blood pressure value for each rat in each session was the average of three consecutrve measurements
Adrenal Weights and Tissue Preparation
After recording of mtra-arterial MAP and measurement of the pressor effects of angrotensm I and II, the animals were krlled by further inJection of the anesthetic agents A midline abdominal incision was made for removal of the adrenal glands The periadrenal fat was carefully dissected, and the glands were weighed in an analytical scale (Sartorms, Brmkmann Instruments Co, precision, 0 1 mg) and lmmedrately frozen m lquid nitrogen for storage at -80°C The adrenal glands from 5 rats m each group were used to extract RNA for Northern blot analysis cDNA Probes A 0 8-kb fragment (-178 to +562) from the coding region of rat AT,, cDNA*s was used as a template to make AT, probes. A 1 23-kb fragment (+ 16 to +1249) from the coding region of rat AT2 cDNA24 was used as a template to make AT2 probes All probes were labeled wrth [32P]deoxycytrdme trrphosphate (Amersham) by use of a random primer DNA labeling system (Amersham) Umncorporated nucleotrdes were separated usmg a G-50 spm column (Worthington) Northern Blots Total adrenal RNA was extracted usmg the guarudme throcyanate-phenol-chloroform extraction protocol 25 Electrophoresls of 20 pg denatured RNA was carried out m a 1% agarose gel containing 2.2 mol/L formaldehyde RNA was transferred to a positively charged nylon membrane (Fisher Co) The membrane was baked at 80°C for 2 hours m a vacuum oven (Fisher Co), and the blot was prehybridlzed for 5 hours at 42°C m hybridrzatron buffer (50% deromzed formamrde, 5X Denhardt's solution, 5X SSC, 0 5% SDS, and 200 pg/mL denatured salmon sperm DNA), followed by hybrrdrzahon with the "P-labeled probes for 18 to 20 hours at 42°C At the end of this period, the blot was washed successively m 2X, 1X, and 0 5X SSC (two times, 10 minutes each) containing 0 1% SDS at 65'C To control for drfferences m RNA loading, Northern blots were incubated at 90°C for 10 minutes m 20 mmol/L tns (hydroxymethyl) ammomethane HCI (pH 8 0) to stnp off the cDNA probes and later rehybrrdrzed wnh a "P-labeled 18s rRNA probe Autoradrograms were made usmg XAR-5 x-ray film (Eastman Kodak Co) and an mtensrfymg screen Autoradrographic signals were scanned with a laser densitometer (Ultrascan XL Laser Densitometer) Results of relative gene expression are expressed as the ratros of AT, mRNA and AT1 mRNA to 18s rRNA
Statistical Analysis
Results are given as mean-tSEM The significance of changes m a variable from the begmmng to the end of the study was assessed with paired Student's t tests The significance of differences between groups was assessed by ANOVA followed by the Tukey-Kramer multtple comparison test Relationships between variables were assessed by single linear regression analysis. All analyses were run with the JMP (version 3.0.2) statrstrcal package of the SAS Institute Inc A value of P< 05 was used to reJect the null hypothesis (re, no difference between means or no relationship between variables)
Results
Inrtlal body weight was not srgnrficantly different among the four groups of rats (Table) All animals gamed werght over the 3-week course of the experiment. However, the weight gam of the three groups treated with DOC was sigmficantly less than that in controls. There was no difference m body weight gain between DOC, DOC-L, and DOC-R, mdmatmg that blockade of the renm-angrotensm system did not have an effect on this parameter At the end of the study, the three groups of DOC rats had body weights that did not differ among them but were all signrficantly less than that rn controls ( Tail-cuff systolic blood pressures of the DOC, DOC-L, and DOC-R groups were significantly higher than those of controls beginning on days 3, 3, and 7, respectively. Over the remainder of the experiment, systolic blood pressure of the three DOC groups rose similarly (Fig 1) . At the end of the experiment, the values for the four groups were controls, 13924; DOC, 21528; DOC-L, 22617; and DOC-R, 223t7 mm Hg (F=42.4, P<.OOOl, Tukey: all DOC groups higher than controls and not different between them). On day 21, MAP under anesthesia exhibited the same pattern (controls, 98-C 1; DOC, 13123; DOC-L, 12617; and DOC-R, 12624 mm Hg; F=9.7, P<.OOl, Tukey: same as that for tail cuff). Therefore, neither losartan nor ramipril prevented the increase in blood pressure produced by the combined treatment with DOC and salt in uninephrectomized rats, confirming that angiotensin IT is not necessary for the development of hypertension in this model.
MAP responses to bolus injections of angiotensin I (50 rig/kg) were significantly smaller in DOC (26t4 mm Hg) than in controls (41+2), perhaps due to decreased lung angiotensin-converting enzyme levels in DOC.26 Responses to angiotensin I in DOC-L (322) and DOC-R (322) were markedly diminished and significantly smaller than those in controls and DOC. Responses to angiotensin II (50 "g/kg) were not different among controls (49t2), DOC (44%7), and DOC-R (41t4), while those of DOC-L were significantly decreased (1054). These data confirm effective AT, receptor blockade by losartan and inhibition of the angiotensin-converting enzyme by ramipril. Fig 2 shows that the weight of the adrenal gland of DOC-rats (177114 kg/g body wt) was slightly but not significantly greater than that of controls (131 t 13). In contrast, the DOC-L (209tlS) and DOC-R (236% 15) groups exhibited significantly higher adrenal weights than controls, but they were not different between DOC-L and DOC-R. Thus, we found that losartan and ramipril promoted enlargement of the adrenal gland, suggesting the presence of a growth-inhibitory action of angiotensin II on this organ.
AT, and AT2 mRNA levels in the adrenal glands were determined by Northern blot analysis in the four experimental groups (Fig 3A) . Blots were then stripped and re- hybridized to 18s mRNA probes. Densitometric analysis indicated that the AT1 mRNA/lSS rRNA ratios differed in the four groups (F-19.9, P<.OOOl, Fig 3B) . AT, mRNA/ 18s rRNA ratio of DOC (1.07+0.06) was significantly lower than that in controls (1.61tO. 16), a decrease of 33%. In DOC-L (0.67-CO.05) and DOC-R (0.74?0.07), AT, mRNA/lW rRNA ratios were further diminished, significantly differing from those of DOC and controls. AT2 mRNA/lSS rRNA ratios were also different among the four groups (F= 12.0, P<.OOO2, Fig 3C) . AT2 mRNA/lSS rRNA ratio of DOC (0.82-~0.08) was significantly lower than that in controls (2.02+-0.28), a decrease of 60%. AT2 mRNA/I8S rRNA ratios of DOC-L (0.63-CO.08) and DOC-R (0.731-0.22) were also significantly lower than that in controls but not significantly decreased from that of DOC. There were no correlations between adrenal AT, mRNA/I 8s rRNA or AT2 mRNA/I 8s rRNA ratios and blood pressures (tail cuff or intra-arterial) in control or DOC-treated animals. In contrast, significant negative correlations were detected, for all animals analyzed together, between the weight of the adrenals (normalized per gram of body weight) and the AT1 mRNA/IXS rRNA (r= -JO, P<.OOOl) or AT2 mRNA/18S rRNA (r=-.60, P<.OO5) ratios, Fig 4. 
Discussion
Most reports suggest that the growth-promoting and antiproliferative actions of angiotensin II are exerted via its AT, and AT2 receptors, respectively.8.l' However, there are exceptions for both these subtypes in vascular tissues.1*J3 In adrenocortical cells in culture, AT, stimulates proto-oncogene expression'8 and mediates proliferative effects. 17 No action has been described, either on growthpromoting or inhibiting processes, for AT2 in these in vitro preparations.
The DO&ah rat is an ideal model for the in vivo study of regulation of adrenal growth by the renin-angiotensin system because plasma renin is profoundly suppressed during the early stages of the hypertension,*' while the components of the tissue renin-angiotensin system are still detectable in several organs,*'-29 including expression of renin mRNA in the adrenal gland.30 Therefore, we speculated that this model would permit investigation of the effects of ra- and DOC given ramipril (DOC-R).
B, Densitometric data in which AT, mRNA levels were normalized by 1% rRNA in each of the four groups. The results are expressed as meanGEM; n=5 rats per group. *All three DOC groups significantly less than C; tDOC-L and DOC-R significantly less than DOC.
C, Densitometric data on AT* mRNA levels normalized by 18s rRNA. Data given as in 38. *Significantly different from C and not sianificantlv different among the three D6C grou& i C DOC DOGL DOGR mipril and losartan on adrenal growth via actions on the local adrenal renin-angiotensin system and without the confounding effects of changes in blood pressure. We confirmed that neither ramipril nor losartan modified the development of hypertension in our DOC-salt rats, as reported previously with other converting enzyme inhibitors and AT, receptor blockers.*l,** In this regard, the DOC-salt model is unique among low-renin models of experimental hypertension. Rats subjected to partial renal ablation and Dahl-S rats given salt also develop hypertension with decreased plasma renin, but they exhibit blood pressure reduction in response to converting enzyme inhibitors and AT, receptor antagonists.31-33
It has been reported that the adrenal gland of DOC-salt rats sustains a decrease in weight during the development of hypertension, 19 a change that is prevented by coadministration of angiotensin I.20 We could not confirm these observations in our DOC-salt rats. They actually sustained a mild increase (albeit not statistically significant) in adrenal weight compared with controls. In one of the previous publications, adrenal weights were not normalized to body weights,'9 and in the other, there were methodological differences with our experiments (Wistar rats instead of Sprague Dawley, and repeated subcutaneous injections of DOC instead of pellet implantation).*0 We cannot speculate whether these differences account for the conflicting results.
The major findings of our experiments can be summarized as follows: (1) DOC-rats without pharmacological blockade of the renin-angiotensin system exhibited significantly reduced expression of AT, and AT2 genes in the adrenal gland compared with controls; (2) losartan and ramipril decreased AT1 (but not AT2) gene expression further, beyond the decrease observed in untreated DOC-rats; (3) in all DOC-rats and controls, analyzed together, there were inverse relationships between the weight of the adrenal glands and AT1 or AT2 gene expression; and (4) losartan and ramlpril produced a significant enlargement of the adrenal glands Taken together, these observations suggest that angiotensm II exerts a tonic growth-inhibitory effect on the adrenal gland, which 1s medlated by the ATI receptor (increased adrenal weight by losartan) and perhaps also by AT2 (inverse relationship between AT:! and adrenal weight), although confirmation of the latter would require the use of specific AT2 antagonists. Decreases m the expression of these receptors, of the magnitude observed in DOC-salt rats, were not enough to produce a statistically significant enlargement of the adrenal gland m the small group of animals studied In contrast, with further decrease in expression of the ATI gene by losartan and ramlpnl, there was significant enlargement of the adrenal gland, which was possibly enhanced by dtmmished action of angiotensm II on AT1 (losartan) or by decreased tissue generatlon of this peptlde (ramlpnl) It IS unhkely that downregulatlon of AT, or AT, was due to DOC because (1) only the glucocortlcold receptor regulates angiotensin receptor gene expression,34 (2) a GRE IS only present m the gene for the AT,* receptor subtype, and (3) bmdmg of the glucocortlcold receptor to this GRE stimulates gene transcnptlon,34 which 1s not consistent with dimmlshed receptor expression observed m our DOC-salt rats Opposing effects of nephrectomy on adrenal anglotensm receptor bmdmg have been described UpregulatIon was attributed by some to high serum potassmm,35 which 1s consistent with upregulation of adrenal AT, mRNA and protein by high potassium diet m normal rats 36 Others have attributed observed downregulation of receptor bmdmg37 and receptor mRNA3* to decreased anglotensm II Although those results were obtained m anephnc, not unmephrectomlzed, rats, they are applicable to interpretation of our findings It 1s conceivable that low serum potassmm and low circulating anglotensm contributed to downregulatlon of adrenal anglotensm II receptors in DOC-salt rats
The most likely factor responsible for adrenal downregulation of both AT, and AT2 m DOC-salt rats 1s high sodmm mtake, perhaps enhanced by the salt-retammg properties of DOC In normal rats, adrenal anglotensm II lmmunoreactlvlty and anglotensm receptor bmdmg correlate closely and are diminished by a high salt diet.39 An effect of high salt diet on anglotensm gene expression has not been reported, but low-sodium diet upregulates adrenal ATIA and AT,a receptor mRNA,40 AT2 hgand bmdmg,lo and AT, receptor protein.36 Captopril36 and losartan41 prevent the effects of low-salt diet, mdlcatmg that adrenal angiotensm receptor upregulation 1s due to increased anglotensm II by sodium deprivation This has been confirmed by &rect demonstration of adrenal anglotensin receptor upregulatlon by mfuslon of anglotensm II.38 These findmgs make It hkely that suppresslon of clrculatmg and/ or tissue angiotensm II by high salt diet and DOC was the major factor determmmg downregulation of AT, and AT2 m our DOC-salt rats They are also consistent with further reduction of AT, expression by admmlstratlon of losartan or ramlprll to these animals Although ours 1s the first report in DOC-salt rats, others have shown downregulatlon of adrenal AT, but not AT1 by losartan,Q of both AT, and AT2 by hsmoprl1,4* and of the AT,* and ATIB subtypes by delaprll 43 In the present experiment, losartan and ramlpnl downregulated the AT, receptor beyond the decrease produced by DOC-salt. In contrast, downregulatlon of AT2 by DOC-salt was not augmented by these compounds This difference could be due to the more profound downregulatlon of AT, by DOC-salt, compared with AT1, which may have made it more difficult to detect further changes m AT2 mRNA after blockade of the rerun-anglotensm system It is also possible that downregulatlon of AT1 by hrgh salt-&et 1s dependent on withdrawal of anglotensm II or of its action, while that of AT2 reflects an anglotensmindependent action of sodium. We do not have data to support either posslblhty.
An addltlonal factor, norepmephrme stimulation of alpha-l adrenoceptors, may contrlbute to downregulatlon of adrenal AT1 m DOC-salt rats. These animals exhlblt exaggerated norepmephrme release mto the synaptic cleft, with splllover to the clrculatlon 44 In normal rats, prazosm enhances expression of adrenal ATIA and ATIs, demonstrating an alpha-l mhlbltory action of norepmephnne on gene expression of AT, receptor subtypes 45
Regardless of its mechanisms, downregulatlon of adrenal expression of anglotensm II receptors has been now described m three models of experimental hypertension Adrenal ATIB mRNA (but not AT,*) 1s decreased by 50% m Goldblatt two-ludney, one clip hypertension of Wlstar rats,40 adrenal AT1 by 66% m hypertensive rats due to reduced renal mass and high sodium intake,32 and adrenal AT, by 33% and AT2 by 60% m DOC-salt rats m the present experiment. These models encompass the full spectrum of plasma remn actlvlty or renm dependence of blood pressure and differ m the mechanisms of their hypertension This suggests that downregulatlon of adrenal angiotensin receptor genes may play an as yet unknown compensatory role m expenmental hypertension In contrast, m spontaneously hypertensive rats, adrenal ATI receptors are more abundant than m Wlstar-Kyoto controls,'4 suggesting that alterations m anglotensm receptor gene expression may play a pathogenic rather than a compensatory role m genetic hypertension
In conclusion, we have shown that DOC-salt hypertension m the rat exhlblts downregulatlon of adrenal expression of AT, and AT2 In the case of AT,, this downregulatlon seems to follow the same pattern as m normal rats, le, It 1s most likely dependent on removal of the action of anglotensm II by salt and DOC A role for anglotensm m downregulatlon of adrenal AT?, mRNA was not demonstrated by these experiments We also show that downregulatlon of these receptors by DOC-salt hypertension seems to withdraw a growth-mhlbltory influence that anglotensm II exerts on the adrenal gland. This becomes more apparent after more profound downregulatlon of the AT, (not the AT,) receptor by blockade of the renm-anglotensm system The effect of losartan on adrenal weight makes it unequivocal that the AT, receptor mediates the growthinhibitory action of anglotensm II on the adrenal gland, provldmg another example of an exception to the usual growth-promotmg effects of this receptor
